<DOC>
	<DOCNO>NCT02188784</DOCNO>
	<brief_summary>The purpose study determine oral iron ( FE ) polysaccharide superior oral placebo improve functional capacity measure change peak VO2 CPET ( Cardiopulmonary Exercise Testing ) , broad population patient HFrEF ( Heart Failure Exercise Testing ) Fe deficiency 16 week . Hypothesis : In broad population HFrEF patient Fe deficiency , compare oral placebo , therapy oral Fe polysaccharide associate improvement functional capacity 16 week assess CPET .</brief_summary>
	<brief_title>Oral Iron Repletion Effects On Oxygen Uptake Heart Failure</brief_title>
	<detailed_description>Therapeutic option improve functional capacity symptom HF beyond neurohormonal antagonism limit . Studies demonstrate impaired oxidative capacity skeletal muscle among HF patient , may contribute symptom breathlessness persistent fatigue . In addition role erythropoiesis , iron ( Fe ) play critical role skeletal muscle 's oxygen ( O2 ) -storage capacity ( myoglobin ) systemic aerobic energy production . As Fe deficiency common patient symptomatic HF , repletion iron store may improve submaximal exercise capacity among patient beyond effect erythropoiesis . While intravenous Fe repletion HF patient mild Fe-deficiency ( i.e . Ferritin &lt; 100 Ferritin 100-299 transferrin saturation &lt; 20 % ) without anemia global well-being functional status , oral Fe repletion study . Furthermore , efficacy oral Fe replete iron store similar population impact functional capacity , measure objectively peak VO2 , remain unknown .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Previous clinical diagnosis heart failure current NYHA Class IIIV symptom LVEF≤0.40 within 2 year prior consent , ≥3 month major change cardiac status ( i.e . CABG CRT ) . 3 . Serum ferritin 15100 ng/ml serum ferritin 100299 ng/ml transferrin saturation &lt; 20 % 4 . Hemoglobin 9.013.5 g/dL ( male ) , 913.5 ( female ) time enrollment 5 . Stable evidencebased medical therapy HF ( include betablocker ACEinhibitor/ARB unless previously deem intolerant , diuretic necessary ) &lt; /= 100 % change dose 30 day prior randomization . Changes diuretic dose guide patientdirected flexible dose program consider stable medical therapy 6 . Willingness provide informed consent 1 . Presence neuromuscular , orthopedic noncardiac condition prevents patient exercise test bicycle/treadmill ergometer and/or inability achieve RER ≥ 1.0 screening/baseline CPET 2 . Severe renal dysfunction ( eGFR &lt; 20 ml/min/1.73m2 ) 3 . Severe liver disease ( ALT AST &gt; 3x normal , alkaline phosphatase bilirubin &gt; 2x normal ) 4 . Gastrointestinal condition know impair Fe absorption ( i.e . inflammatory bowel disease ) 5 . Known active infection define current use oral intravenous antimicrobial agent 6 . Documented active gastrointestinal bleeding 7 . Active malignancy nonmelanoma skin cancer 8 . Anemia know cause Fe deficiency chronic disease 9 . Fe overload disorder ( i.e . hemochromatosis hemosiderosis ) 10 . History erythropoietin , IV oral Fe therapy , blood transfusion previous 3 month . 11 . Current ventricular assist device 12 . Anticipated cardiac transplantation within next 4 month 13 . Primary hypertrophic cardiomyopathy , infiltrative cardiomyopathy , acute myocarditis , constrictive pericarditis tamponade 14 . Previous adverse reaction study drug oral Fe preparation 15 . Known anticipated pregnancy next 4 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>